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Structured abstract 
 
Aims:  While glucocorticoids are widely used to treat patients with various diseases, they 
often cause adverse effects such as bone fractures.  In this study, we investigated whether the 
decrease in bone density induced by glucocorticoid therapy was ameliorated by optimizing a 
dosing-time. 
Main methods:  Rats were administered with dexamethasone (Dex) orally (1 mg/kg/day) for 
6 weeks at a resting or an active period.  After the end of the treatment, bone density of 
femur, biomarkers of bone formation and resorption, and other biomedical variables were 
measured. 
Key findings:  Bone density of femur was significantly decreased by the 6-week treatment 
with Dex, and the degree of decrease in the 14 HALO (hours after light on) dosing group (an 
active period) was larger than that in the 2 HALO dosing group (a resting period).  Although 
urinary calcium excretion was accelerated by Dex treatment, secondary hyperparathyroidism 
was not detected.  Histomorphometry analysis showed that Dex suppressed bone resorption, 
which was larger in the 2 HALO than in the 14 HALO groups.  These data indicate that Dex 
equally suppressed bone formation in the 2 and 14 HALO groups, but inhibited bone 
resorption more in the 2 HALO than in the 14 HALO groups. 
Significance:  This study shows that the decrease in bone density induced by Dex was 
changed by its dosing-time. 
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Introduction 
 
Glucocorticoids (GCs) are widely used to treat patients with inflammatory disorders such 
as obstructive airway disease, rheumatoid arthritis and inflammatory bowel diseases. 
Unfortunately GCs cause several kinds of adverse effects involving hyperglycemia, 
hypertension and sleep disturbance (Andrews and Walker 1999; Ling et al. 1981; Whitworth 
et al. 2000).  It is well known that the repeated treatment with GCs also increases the risk of 
bone fractures (Kanis et al. 2004; Van Staa et al. 2000a), which is dose-dependent and occurs 
rapidly after the initiation of the treatment (Van Staa et al. 2000b).  In addition, a recent 
database analysis showed that the high-dose of oral GCs leads to the increased risk of 
osteoporotic fracture (De Vries et al. 2007). 
Bone metabolism is a dynamic and continuous remodeling process that is normally 
maintained in a tightly coupled balance between the resorption of old or injured bone and the 
formation of new bone (Dempster 1992).  In brief, osteoclast precursors are recruited to a 
bone surface (activation), and then the newly formed osteoclasts remove both the mineral and 
organic components of bone matrix (resorption).  Osteoblasts and their precursor assemble to 
refill the resorption cavity.  Bone formation is beginning with the deposition of osteoid by 
the osteoblasts, and then the second stage is mineralization of the organic matrix.  Bone 
remodeling serve two principal functions as follows: renewing the skeleton continuously, and 
playing a role in mineral homeostasis by transferring calcium and other ions. 
It is important to increase the therapeutic effects of drugs and to decrease their adverse 
effects.  Chronotherapy is one of the approaches to achieve these goals by optimizing a 
dosing-time.  We already demonstrated the merits of chronotherapy using several drugs in 
animals and human subjects (Kitoh et al. 2005; Nozawa et al. 2006; Tsuruoka et al. 2004b; 
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Ushijima et al. 2005).  Dosing-time dependent changes in the pharmacokinetics and/or 
pharmacodynamics are mainly involved in chronopharmacological phenomenon of drugs 
(Lemmer 2005). 
There are many reports indicating that the circadian rhythmicity is a typical feature of bone 
metabolism.  For example, plasma concentrations of calcium and its regulating hormones 
(Fraser et al. 1998; Mühlbauer and Fleisch 1995), and markers of bone formation and 
resorption (Greenspan et al. 1997; Nielsen et al. 1991; Shao et al. 2003; Blumsohn et al. 1994; 
Bollen et al. 1995) showed circadian rhythms.  In addition, the influences of drugs on bone 
metabolism are reported to be altered by their dosing-time (Schlemmer et al. 1997; Tsuruoka 
et al. 2002, 2004a, 2004b, 2007).  Based on these data, we hypothesized that the decrease in 
bone density induced by GCs therapy is ameliorated by optimizing a dosing-time. 
To address this issue, we examined the influence of GC dosing-time on the decrease in 
bone density, and evaluated a potential mechanism involving in this phenomenon.  In this 
study, we used dexamethasone, which is a potent synthetic member of the glucocorticoid 
family. 
 - 5 - 
Materials and Methods 
Animal and chemicals 
Six-week old male Wistar rats were obtained from Japan SLC Co. (Shizuoka, Japan).  
They were maintained for more than 2 weeks before the experiment in two rooms under a 
specific pathogen-free environment and a 12-hour light/dark cycle. The lights were switched 
on and off at 07:00 and 19:00 in room 1, and at 19:00 and 07:00 in room 2.  Rats had free 
access to standard chow and water.  Chow diet used in this study (CE-2, Crea Japan, Tokyo, 
Japan) contained 1.06% of calcium, 0.98% of phosphorus and 220IU/100mg of Vitamin D.  
The experiments were performed in accordance with EC Directive 86/609/ECC and the Use 
and Care of Experimental Animals Committee of Jichi Medical University (Tochigi, Japan).  
Dexamethasone (Dex) was purchased from Sigma-Aldrich (St Louis, MO), and was 
suspended in the distilled water.  Calcein was obtained from Wako Pure Chemical Industries 
(Osaka, Japan) and dissolved in 2% NaHCO3 solution. 
 
Drug dosing and sample collection 
After the acclimatization period, rats (n=24) were divided into four groups, and Dex (1 
mg/kg p.o.) or vehicle was given by a gastric gavage at two different times [2 or 14 hour after 
lights on (HALO), Fig. 1] once a day for 6 weeks; 
Group 1: vehicle at 2 HALO (n=6), Group 2: Dex at 2 HALO (n=6), 
Group 3: vehicle at 14 HALO (n=6), Group4: Dex at 14 HALO (n=6). 
At the final day, rat was administered with 3% of body weight of deionized water at 30 min 
after dosing and separately placed in a metabolic cage for 4 hours to collect urine sample.  
Twenty four hours after the last dosing, rat was anesthetized with pentobarbital sodium (50 
mg/kg i.p.), and femur and blood were collected.  Femur was stored in 70% ethanol, and 
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serum samples were stored at -80 oC until assay. 
For histomorphometry analysis, rats (n=12) were divided into four groups and received the 
dosing of Dex or vehicle for 6 weeks as described above.  Animal was injected with calcein 
(8 mg/kg i.p.) at 10 and 3 days before the last dosing.  Twenty four hours after the last 
dosing, femur was obtained. 
 
Measurement of femur bone density 
The bone density of femur was determined by dual energy X-ray absorption (DCS-600A, 
Aloka, Japan).  The scan was performed every 2 mm along the axis of the bone from 
proximal end, and 18 scans were obtained for each bone.  Average of the first proximal 3 
scans, middle part of 4 scans, and the last part of 3 scans were regarded as “proximal”, 
“medial” and “distal”.  Average of all scans in bone was shown as “whole”.  “Medial” is 
exclusively cortical bone and “distal” is rich in cancellous bone (Tsuruoka et al. 2002). 
 
Assays 
Serum osteocalcin concentration was determined by ELISA using a commercialized kit 
(Biomedical Technologies Inc., Stoughton, MA).  Assay was performed according to the 
instruction manual.  The intra- and inter-assay coefficients of variation were better than 7%. 
Urinary C-terminal telopeptides of type I collagen (CTx) concentration was measured by 
ELISA using a commercialized kit (RatLaps™ EIA, Immunodiagnostic systems, Tyne and 
Wear, UK).  Creatinine concentration in urine was measured by an enzyme method (Sekisui 
Medical Co., Ltd., Tokyo, Japan) by an autoanalyzer. The value of urinary CTx was corrected 
by creatinine concentration. 
Calcium concentration in serum and urine was measured by the orthocresolphthalein 
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complex method (Mitsubishi Kagaku Iatron, Inc., Tokyo, Japan) with an autoanalyzer (7170, 
Hitachi Ltd., Tokyo, Japan).   
Serum parathyroid hormone (PTH) concentration was determined by an 
immunoradiometric assay (Rat PTH IRMA kit, Immunotopics, Inc., San Clemente, CA).  Its 
normal range was 10-40 pg/ml in rats (Tsuruoka, et al. 2002). 
 
Bone Histomorphometry 
Femur was fixed in 70% ethanol and embedded in glycolmethacrylate without 
decalcification, and sectioned in 3-mm slices.  The sections were stained with Toluidine blue 
not only to discriminate between mineralized and unmineralized bone, but to identify cellular 
components.  Histomorphometry was performed with semiautomated image analyzing 
system (OsteoplanII; Carl Zeiss, Thornwood, NY), which was linked to a light microscope at 
200-fold magnification.  Parameters using the trabecular bone were measured in an area 2.4 
mm in length from 0.6-1.2 mm below the growth plate.  The following parameters were 
calculated; trabecular bone volume expressed as a percentage of total tissue volume (BV/TV), 
percentage of osteoid volume (OV/BS), percentage of osteoid surface (OS/BS), percentage of 
osteoblasts surface (Obs/BS), number of mature osteoclasts in 10 cm of bone perimeter 
(N.Oc/B.Prr), percentage of bone surface covered by mature osteoclasts (OcS/BS) and 
percentage of eroded surface (ES/BS).  The thickness of the epiphyseal growth plate 
cartilage was measured over a length of approximately 2.5 mm in visual areas.  The number 
of proliferative cells and hypertrophic cells was counted in the same visual areas of 0.6 mm 
inside from epiphyseal side, and were expressed as the average values in six to nine clearly 
visible columns. 
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Statistical analysis 
  Data are shown as the means ± S.D.  Comparisons between two groups were done by 
one-way analysis of variance followed by Bonferroni-Dunn test using StatView (SAS Institute, 
Cary, NC).  P <0.05 was considered to be significant. 
 
 
Results 
Influence of Dex dosing-time on bone density of femur 
Bone densities of femur in the vehicle-treated rats were not significantly different between 
the 2 and 14 HALO groups.  Repeated treatment with Dex decreased bone density in the 2 
and 14 HALO groups (Fig. 2). The parameter in the 14 HALO group was lower than that in 
the 2 HALO group, especially in “distal”, “medial” and “whole” sections. 
 
Influence of Dex dosing-time on body weight and food intake 
  The body weights of Dex-treated groups similarly decreased during the experiment period 
while the parameter in the vehicle-treated groups increased (Fig. 3).  Food intake did not 
significantly differ at any observation points between the vehicle and Dex groups. 
 
Influence of Dex dosing-time on serum osteocalcin concentration 
To evaluate the influence of Dex on the bone formation, serum osteocalcin concentration 
was measured.  Serum osteocalcin concentration was significantly decreased by Dex 
treatment in the 2 and 14 HALO groups (Fig. 4).  There was no significant difference in this 
parameter between the two groups. 
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Influence of Dex dosing-time on urinary calcium excretion, and serum concentrations of 
PTH and calcium  
The ratio of u-calcium/u-creatinine was significantly increased in the Dex dosing group at 
14 HALO, but not at 2 HALO (Fig. 5a).  Serum PTH concentrations in the Dex-treated 
groups elevated, but it did not reach to a statistical significance (Fig. 5b).  However, serum 
calcium concentrations in the Dex-treated groups were significantly higher than those in the 
vehicle groups (Fig. 5c). 
 
Influence of Dex dosing-time on urinary CTx concentration 
  To evaluate the influence of Dex on bone resorption, urinary CTx concentration was 
measured.  Urinary CTx concentration tended to be decreased by Dex treatment in the 2 and 
14 HALO groups (Fig. 6). 
 
Influence of Dex dosing-time on histomorphometry of trabecular bones of femur 
Histomorphometory data did not significantly differ between the vehicle-treated 2 and 14 
HALO groups (Table 1a).  Bone volume (BV/TV) of the Dex-treated group at 14 HALO was 
significant lower than that in the vehicle group, while the parameter in the 2 HALO group did 
not significantly decrease.  The percentage of osteoid volume (OV/BS), percentage of 
osteoid surface (OS/BS), percentage of osteoblasts surface (Obs/BS) and the numbers of 
mature osteoclasts (N.Oc/B.Prr) were significantly decreased by Dex treatment in both groups.  
However, bone surface covered by mature osteoclasts (OcS/BS) and consequent eroded 
surface (ES/BS) were significantly reduced by the treatment with Dex at 2 HALO, but not at 
14 HALO.   
Histomorphometory data of the epiphyseal growth plate cartilage were shown in Table 1b.  
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The thickness of growth plate cartilage and the number of proliferative cells per cell column 
were significantly decreased by the Dex- treated 2 and 14 HALO groups. There were no 
significant differences in these parameters between the 2 and 14 HALO groups with Dex. 
 
Discussion 
As a preliminary study, we tested the 0.1, 0.32 and 1 mg/kg of Dex administration for 6 
weeks at 2 HALO, and found that only 1 mg/kg of Dex caused a significant decrease in bone 
density of femur (data not shown).  Therefore, we selected the 1 mg/kg of Dex 
administration for 6 weeks in this study.  The preliminary study also showed that body 
weights were decreased by 0.32 and 1 mg/kg of Dex in rats.  These data suggest that the 
kinds of Dex-induced adverse effects depend on its dose.  Although body weights were 
decreased by Dex treatment at 2 and 14 HALO in this study, food intake did not be decreased 
by Dex treatment at any observation points, which indicates that Dex-induced bone loss might 
not be due to a reduced nutrition. 
In this study, Dex treatment for 6 weeks reduced bone density of femur in rats.  Similar 
findings were reported as follows; 1) Methylprednisolone reduced the bone mechanical 
strength due to the decreased bone quantity and quality (Ortoft and Oxlund 1988).  2) 
Repeated treatment with prednisolone caused osteopenia (Lindgren et al. 1983; Goulding and 
Gold 1988).  However, King et al reported the opposite observation that Dex treatment 
increased the trabecular bone volume both in intact and parathyroidectomized rats (King et al. 
1996).  In their study, Dex was given continuously by an osmotic pomp, and a dose of Dex 
(16.25 µg/rat/day) was small.  Although we did not have any definite explanations for the 
discrepancy of the influence of GCs on bone tissue, it may reside in the differences in the 
dose of GC and its dosing route. 
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GCs influence the bone metabolism through the multiple pathways as follows; 1) Direct 
inhibition on the proliferation of osteoblast (Canalis 1996; Leclerc et al. 2005), 2) 
Hyperparathyroidism induced by the direct effect on parathyroid gland (Zhang et al. 1993) or 
the GCs-related increase in urinary calcium excretion (Canalis 1996; Reid 1997), and 3) 
Direct stimulation (Kaji etb al. 1997; Takuma et al. 2003) or inhibition (Dempster et al. 1997; 
Kim et al. 2006) on the formation of osteoclast. 
Dex-induced decrease in bone density in the 14 HALO group was larger than that in the 2 
HALO group in this study. To evaluate the mechanism(s) involving in the dosing-time 
dependent change in the effect of Dex on bone density, we examined the influence of its 
dosing-time on bone formation.  GCs directly impair the proliferation of osteoblasts and 
subsequently reduce the number and function of mature osteoblasts leading to a decrease in 
osteocalcin transcription (Canalis 1996; Leclerc et al. 2005).  In this study, we measured 
serum osteocalcin concentration, a biomarker of osteoblasts after 6-week of dosing.  The 
parameter was significantly decreased by the treatment with Dex, but there was no significant 
difference between the 2 and 14 HALO groups.  Therefore, a dosing-time dependent change 
in the effect of Dex on bone formation might not be involved in the mechanism of this 
phenomenon. 
GCs increase urinary calcium excretion by the direct effect on the kidney, which leads to 
secondary hyperparathyroidism (Canalis 1996; Reid 1997).  Hyperparathyroidism, in turn, 
activates osteoclasts, which accelerates calcium release from bone tissue and consequently 
causes bone fracture.  Thus, the increased urinary calcium excretion is likely a marker of 
bone loss induced by Dex.  In this study, we determined whether the effect of Dex on the 
urinary calcium excretion and serum PTH concentration were influenced by its dosing-time.  
The urinary calcium excretion significantly elevated in the Dex-treated 14 HALO group, and 
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tended to elevate in the Dex-treated 2 HALO group.  These data led us to speculate that Dex 
dosing at 14 HALO caused hyperparathyroidism, which resulted in the decrease of bone 
density.  However, serum PTH concentration did not elevate by Dex treatment and remained 
within the normal range between 10-40 pg/ml (Tsuruoka et al. 2002) in the 2 and 14 HALO 
groups.  Thus the role of PTH on a dosing-time dependent effect of Dex might be small, if 
any. 
In general, hypercalcemia decreased PTH secretion.  In this study, rats treated with Dex 
showed hypercalcemia and relatively higher PTH concentraion.  It is reported that Dex 
accelerated the secretion of PTH from cultured parathyroid cells and elevated PTH mRNA 
level (Zhang et al. 1993).  Therefore, we think that the direct effect of Dex on parathyroid 
gland is reflected in the relatively higher PTH observed in this study. 
Since serum calcium concentration was significantly elevated by Dex treatment, it was 
speculated that calcium release from bone tissue might be accelerated.  To evaluate a 
dosing-time dependent effect of Dex on bone resorption, we measured urinary CTx 
concentration, a marker of bone resorption, and performed the histomorphometry analysis 
using a fluoroscent reagent, calcein.  Although all parameters of bone resorption in 
histomorphometry analysis were decreased by Dex treatment, the degrees of the reduction 
were significantly larger in the 2 HALO than in the 14 HALO groups.  The changes in 
urinary CTx concentration were comparable with the histomorphometry data.  Based on 
these data, we think that the activity of bone resorption was greater in the 14 HALO than in 
the 2 HALO groups.  Histomorphometry analysis showed that the number of osteoblasts was 
significantly reduced by Dex in the 2 and 14 HALO groups, which was identical to the result 
of serum osteocalcin concentration.  In addition, the thickness of epiphyseal growth plate 
cartilage and the number of proliferative cells were similarly decreased by Dex in the 2 and 
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14 HALO groups.  Thus, the Dex-induced suppression on bone formation and epiphyseal 
cartilage metabolism did not differ between the 2 and 14 HALO groups.  These data indicate 
that a dosing-time dependent change in the effect of Dex on bone resorption is involved in 
this phenomenon. 
The effects of GCs on bone resorption are complex and less clear.  Previous in vitro 
studies demonstrated that GCs increase the formation and activity of osteoclasts (Kaji et al. 
1997; Takuma et al. 2003), while other studies showed that GCs inhibit the osteoclasts 
formation by altering the transcription and enhancing apoptosis (Dempster et al. 1997; Kim et 
al. 2006).  Moreover, a higher dose of methylprednisolone (~ 20 mg/kg) reduced the number 
of osteoclasts in rats (Hulley et al. 2002; Wang et al. 2002), but a lower dose of Dex did not 
(King et al. 1996).  These findings and present data suggest that a higher dose of GCs 
inhibits the formation of osteoclasts.  However, because pharmacological dose was used in 
this study, it is unclear whether chronophrmacological phenomena observed in rats are also 
detected in human subjects treated with Dex.  Human study is needed to evaluate a potential 
dosing-time dependent effect of Dex on bone. 
 
Conclusion 
The decrease in bone density induced by Dex was larger in the 14 HALO than in the 2 
HALO groups.  Dex equally suppressed bone formation in the 2 and 14 HALO groups, 
while it inhibited bone resorption more in the 2 HALO than in the 14 HALO groups, which 
might cause the dosing-time dependent effect of Dex on bone loss in rats. 
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Table 1a Bone histomorphometory analysis of trabecular bone in femur 
  2 HALO 
 
14 HALO 
  vehicle Dex vehicle Dex 
BV/TV (%) 19.94 ± 0.51 18.57 ± 1.09 20.48 ± 1.61 16.94 ± 1.06* 
OV/BV (%) 0.417± 0.195 0.018± 0.003* 0.307± 0.137 0.017± 0.198* 
OS/BS (%) 3.76 ± 1.53 0.14 ± 0.04* 2.78 ± 1.24 0.15 ± 0.05* 
Ob.S/BS (%) 4.32 ± 1.88 0.05 ± 0.04* 3.52 ± 1.89 0.19 ± 0.16* 
N.Oc/B.Prr (/100mm) 136.78 ± 37.06 42.11 ± 9.68** 133.24 ± 16.54 64.87 ± 6.94* 
Oc.S/BS (%) 2.81 ± 0.68 0.51 ± 0.08** 1.94 ± 0.649 0.76 ± 0.14 
ES/BS (%) 5.70 ± 0.49 1.57 ± 0.31**, # 4.58 ± 0.85 3.22 ± 0.30 
Mean ± S.D. n=3 in each group 
*, P <0.05, **, P <0.01 vs. vehicle; #, P <0.05 vs. 14 HALO Dex 
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Table 1b Histomorphometory analysis of the epiphyseal growth plate cartilage 
 2 HALO 
 
14 HALO 
 vehicle Dex vehicle Dex 
Thickness (µm) 144.17 ± 15.40 87.15 ± 11.42** 151.41 ± 7.25 95.52 ± 5.11** 
No. of proliferative 
cells per cell column 
7.65 ± 0.51 4.04 ± 0.06**  7.91 ± 0.42 3.94 ± 0.85** 
No. of hypertrophic 
cells per cell column 
3.32 ± 0.39 2.93 ± 0.48  2.81 ± 0.17 2.11 ± 0.11 
Mean ± S.D. n=3 in each group 
**, P <0.01 vs. vehicle 
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Captions 
 
Fig. 1 Schematic representation of two reversed lighting regimens to provide two different 
dosing times at one point.  By reversing the lighting condition in two different rooms, dosing 
at 09:00 approximates the treatment at two circadian stages: 2 and 14 HALO (hour(s) after 
lights on). 
 
Fig. 2 Influence of Dex dosing-time on bone density of femur 
Dex or vehicle was given once daily at 2 HALO or 14 HALO for 6 weeks.    , vehicle at 
2HALO;   , Dex at 2 HALO;   ,vehicle at 14 HALO;   , Dex at 14 HALO.  Mean ± S.D., 
n=6 in each group  *, P <0.05, **, P <0.01 vs. vehicle; #, P <0.05 vs. Dex at 2 HALO 
 
Fig. 3 Influence of Dex dosing-time on body weight and food intake 
 (a, b);   , vehicle;   , Dex.  (c, d);   , vehicle;   , Dex.  Mean ± S.D., n=6 in each 
group  **, P <0.01 vs. vehicle 
 
Fig. 4 Influence of Dex dosing-time on serum osteocalcin concentration 
Mean ± S.D., n=6 in each group  **, P <0.01 vs. vehicle 
 
Fig. 5 Influence of Dex dosing-time on (a) the ratio of urinary calcium/creatinine, (b) serum 
PHT and (c) serum calcium concentration 
Rats were given with 3% of body weight of deionized water at 30 min after the last dosing, 
and placed into a metabolic cage for 4 hr to collect urine.  Blood sample was obtained at 24 
hr after the last dosing. Mean ± S.D., n=6 in each group  *, P <0.05; **, P <0.01 vs. vehicle 
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Fig. 6 Influence of Dex dosing-time on urinary CTx concentration 
Urinary CTx concentration was corrected by creatinine concentration.  Mean ± S.D., n=6 
in each group 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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